Verona pharma reports third quarter 2023 financial results and provides corporate update

Us fda accepted nda filing for ensifentrine for maintenance treatment of copd pdufa target action date of june 26, 2024 commercial launch preparations supported by strong balance sheet conference call today at 9:00 a.m. edt / 1:00 p.m.

VRNA Ratings Summary

VRNA Quant Ranking